Docetaxel Injection is a microtubule inhibitor indicated for...Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC.

Docetaxel Teva is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.

For patients with metastatic NSCLC who progress on combination therapy with PD-1/PD-L1 inhibitors/chemotherapy, subsequent therapy with docetaxel (with or without ramucirumab), pemetrexed (non squamous only), or gemcitabine is recommended...

In this open-label, randomized, phase III study, newly diagnosed patients with advanced NSCLC were initially randomized (R1, 1:1) to receive first-line treatment with cisplatin 75 mg/m2 plus docetaxel 75 mg/m2 (DC75) or 60 mg/m2 (DC60) for up to 4 cycles....DCM significantly prolonged PFS compared to BSC (HR =0.57, median PFS =5.8 vs. 3.0 months, P=0.002)....Continuation maintenance treatment with docetaxel...improves PFS in patients with NSCLC.